Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). The company is set to be listed on the Korea Exchange (KRX) on November 24, 2025, marking a key milestone in Samsung’s long-term biotechnology growth strategy.
Prior to the listing, Samsung Epis Holdings will establish a new subsidiary company on November 14, 2025, designed to strengthen its focus on next-generation biotechnology platforms. Under the new corporate structure, Samsung Bioepis will remain a 100% owned subsidiary of Samsung Epis Holdings and will continue to lead its global biosimilar business.
Kyung-Ah Kim, currently the President and Chief Executive Officer (CEO) of Samsung Bioepis, will also assume the role of President and CEO of Samsung Epis Holdings.
“The new investment holding company will focus on discovering and securing investment opportunities in biotechnology that support the long-term growth of the company and its subsidiaries,” said Kim. “Scientific innovation will remain the cornerstone of our value creation.”
She emphasized that Samsung Bioepis will continue to deliver on its mission of developing, manufacturing, and distributing high-quality biosimilar medicines for patients worldwide. “By establishing an independent decision-making structure, we see strong potential for further growth and investment,” Kim added. “With the spin-off, we expect to gain more flexibility to explore next-generation growth drivers and secure cutting-edge therapeutic technologies, building on the strengths and expertise developed through our biosimilar business.”
Through this restructuring, Samsung Epis Holdings aims to enhance strategic autonomy, optimize business operations, and accelerate innovation across its subsidiaries. The formation of the new holding company represents Samsung’s continued commitment to advancing its position in the global biopharmaceutical industry, while laying the foundation for future breakthroughs in biotechnology and healthcare innovation.
Samsung Epis Holdings Co., Ltd.
As an investment holdings company dedicated to biopharmaceuticals and biotechnology, Samsung Epis Holdings will optimize business strategies for its subsidiaries and maximize corporate and shareholder value through proactive R&D and investment. Samsung Epis Holdings will implement and deploy a focused growth strategy designed to ensure efficient and effective resources while reinforcing the business strategies and platforms for the two subsidiaries.
The New Subsidiary Company
The new subsidiary company under Samsung Epis Holdings will develop next-generation biotechnology platforms targeting various modalities to identify future growth engines beyond the biosimilar business and drive innovation. The new subsidiary will focus on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies.
Samsung Bioepis Co., Ltd.
Samsung Bioepis will continue to focus on its core business, including research and development, manufacturing, supply distribution, and commercialization of biologic medicines. Since its foundation in 2012, Samsung Bioepis has developed the industry’s most rapidly advancing biosimilar medicines portfolio, with 11 biosimilars approved and available around the world. In 2024, the company achieved record-breaking sales of KRW 1.5377 trillion and operating profit of KRW 435.4 billion. Samsung Bioepis will focus on strengthening its development capabilities, with a goal of securing 20+ biosimilars in the long-term. Samsung Bioepis has already opened up access to biologic medicines across immunology, oncology, ophthalmology, hematology, and nephrology, and the company is expanding into other therapeutic areas to address unmet needs of patients.
source link: https://www.businesswire.com/
